PatientsVille.com LogoPatientsVille.com

Breast Cancer | The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer

Breast Cancer research study

What is the primary objective of this study?

Metastatic breast cancer patients with bone involvement who are at high-risk of subsequent skeletal related event (SRE), defined as radiotherapy or surgery to the bone, pathological fracture, spinal cord compression, or hypercalcemia (as reflected through: elevated sCTX or bone pain or a prior SRE despite receiving standard bisphosphonate therapy) should experience a decrease in the surrogate marker, sCTX, at week 12 if switched to zoledronic acid compared with those patients who continue on intravenous pamidronate (i.e. current standard of care). The investigators propose that a drop in sCTX will correlate with improved pain, quality of life and a reduced incidence of further SREs.

Who is eligible to participate?

Inclusion Criteria: 1. Metastatic breast cancer to the bone with radiologically confirmed bone metastases 2. High-risk of subsequent SRE as reflected through either: elevated serum CTX (> 400ng/L) and/or bone pain (using BPI) and/or prior SRE while on bisphosphonate therapy and/or progressive bone metastasis (by imaging) 3. On pamidronate therapy for at least 3 months 4. ECOG ≤ 2 and life expectancy > 3 months 5. Serum creatinine ≤ 2.0 × ULN (zoledronic acid or pamidronate to be renal dosed as per institution standard) 6. No changes in systemic treatment in the 4 weeks prior to study entry or anticipated changes in the 4 weeks after entering the study. Markers of bone formation can be affected by a change in systemic therapies 7. Ability to take calcium and Vitamin D as per Health Canada recommended daily doses for the duration of the study 8. Ability to provide informed consent and complete study evaluations. Exclusion Criteria: 1. Patients with acute symptomatic pathological fractures or acute spinal cord compression until such time as the appropriate management (surgery and/or radiotherapy) has been completed 2. Acute hypercalcemia (>3.5 mmol/L) 3. Hypersensitivity to any bisphosphonate 4. Patients with rapidly progressive non-bone metastases for whom delaying a change in systemic anti-cancer treatment for the 1 month biochemical marker evaluation period could have a detrimental impact on patient outcome. 5. Renal dysfunction (≥ 2x creatinine of the upper limit of normal ) 6. Pregnancy or lactation 7. Patients with dental abscesses or patients potentially requiring tooth extraction while on study

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Breast Cancer

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Pamidronate90mg IV once every 4 weeks for 3 cycles

Drug:Zoledronic acid4mg IV every 4 weeks for 3 cycles

Drug:placebo

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Pamidronate and placeboPatients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.

Zoledronic acid and placeboPatients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.

Study Status

Completed

Start Date: August 2012

Completed Date: January 2016

Phase: Phase 4

Type: Interventional

Design:

Primary Outcome: sCTX values

Secondary Outcome: Palliative response

Study sponsors, principal investigator, and references

Principal Investigator: Mark Clemons, Dr.

Lead Sponsor: Ottawa Hospital Research Institute

Collaborator: Canadian Breast Cancer Foundation

More information:https://clinicaltrials.gov/show/NCT01907880

Discuss Reclast